Tecnologías del Centro de Biotecnología y Bioingeniería CeBiB

al Hy ur a ic on c id

Hyaluronic Acid Production From new raw materials

Research Group University University of Chile Researchers Juan A. Asenjo Barbara Andrews Daniela Vaisman Contact techtransfer@cebib.cl mguerrahevia@ing.uchile.cl +562 29780739

Potential Market Active ingredient of cosmetic products for the treatment of wrinkles and scars. Therapeutic treatments for osteoarthritis, arthritis, gingivitis, wounds and ulcers for humans and

animals. Drug delivery. Dental and ophthalmological fillings for humans and animals. Tissue engineering for adhesive prevention and dermal fillers.

Market Size

Industry Pharmaceutical, cosmetic, veterinary and medical.

1

The global hyaluronic acid (HA) market was valued at close to USD 6.50 billion in 2014 and is expected to reach approximately

USD 10.90 billion by 2020, growing at a CAGR of around 9% between 2015 and 2020. Its price rises above USD 100,000 per kilogram.

2

3

Development stage TRL 4 / Validation of laboratory components.

Global Hyaluronic Acid Market (2014-2020)

10.9 Intellectual property No patents.

USD BILLION

6.5

2014

2015

2016

Source: Zion Research Analysis 2016

www.cebib.cl

2017

2018

2019

2020

Description Construction of genetically modified strains of E. coli.

The first strain, optimized by adaptive evolution in order to get higher specific growth rate with xylose as carbon source (commonly found in forest residues). The second strain was modified to degrade mannitol and alginate from brown algae, as a carbohydrate source. These bacteria were modified with the hasA gene from Streptococcus pyogenes to synthesize hyaluronic acid. Both strains produce hyaluronic acid; high yields are achieved using the first strain. Purification is a simple process and can achieve high performance without generating toxic waste. A non-pathogenic bacterium is used, with fast growth and simple nutritional and growth requirements.

Opportunity HA characteristics depend on its molecular weight, which defines its commercial applications. These are still under study, so it is important to control the molecular weight in an efficient production process without toxic residues. Current production is mainly based on polymer extraction from animal tissues (rooster combs, vitreous humor, etc.), processes with high contamination risks and that generate a molecular weight polydispersity in the product. The most

Relevant Characteristics

Simple and scalable process for non-animal sources of hyaluronic acid, free of toxic compounds.

The developed technology includes simple purification steps, without the generation of toxic waste and using a non-pathogenic, easy to grow bacterium.

similar process currently in use at an industrial level is based on the microbial fermentation of Streptococcus zooepidemicus, which is limited by the high cost of its culture medium. The microorganism is pathogenic for humans and the HA obtained presents molecular weight polydispersity. This is why the development of new production techniques from sustainable raw materials is an alternative to current production methods.

Next Steps To design the intellectual property protection strategy and bring production to a pilot level based on the conditions optimized in the laboratory.

Contact

MarĂ­a Isabel Guerra Technology Transfer Manager

mguerrahevia@ing.uchile.cl +569 8472 3757 +562 2978 0739

www.cebib.cl

p Pe es t id

High Performance Recombinant Peptide Production system Research Group

Potential Market

University University of Chile

Active ingredient of cosmetic products and diagnostic medical devices. Therapeutic (cancer, autoimmune diseases, etc.), antibacterial and agricultural peptides.

Researchers Barbara Andrews Juan A. Asenjo Vida RodrĂ­guez

Efficient production of mediumto large-sized peptides for industrial manufacture and laboratory applications

The global market for therapeutic peptides in 2013 was valued at US $ 18.9 billion and is expected to reach USD 23.7 billion by 2020, with an annual growth rate of 2.8%. The main drivers of market growth are the high prevalence of chronic, cardiovascular disease and cancer. The latter is responsible for

www.cebib.cl

21% of the market of therapeutic peptides. Additionally, the peptides are widely used in cosmetics and medical diagnostic devices.

In terms of applications, current trends suggest that the market will grow as research in therapeutics, antibacterials and agriculture continues to expand.

Global Therapeutics Peptide Market (2013-2020)

23.7 18.9

2013

2015

Pharmaceutical, cosmetic, medical.

1

Market Size

USD BILLION

Contact techtransfer@cebib.cl mguerrahevia@ing.uchile.cl +562 29780739

Industry

2016

2017

2018

2019

2020

2

3

Development stage TRL 4 / Validation of laboratory components.

Intellectual property No patents.

Description The peptides (between 30 and 50 amino acids) cannot be produced by traditional recombinant methods, and their chemical synthesis is inefficient and costly.

Our process presents a new platform for peptide synthesis using E. coli and the design of expression vectors including both a localization and purification signal. The recombinant expression system and high performance purification process were designed and successfully implemented. The system produces peptides in an insoluble form through the fusion to a specific protein with a hexahistidine tail aimed for purification, and fused to a penetratin. High yields of recombinant purified peptides were obtained in both cases.

Relevant Characteristics With the development of this technique a recombinant peptide production process with high yield and purity is sought.

This system will allow considerable savings in the production process of peptides, especially in areas such as the pharmaceutical industry. Additionally, the process is a clean alternative since it does not include the reagents that are commonly used in chemical synthesis, generating comparatively marginal industrial waste.

Opportunity Great efforts are currently being made in R&D for the discovery of new and effective therapeutic peptides. To date (2016) there are 67 peptides marketed in clinical phases, 150 and 400 in advanced preclinical phases. These are chemically synthesized or obtained through genetic recombinant methods. Manufacturing methods are costly (~US$80/ mg), their half-lives are short and their body removal rates are fast, which implies that large quantities are required (~1kg), even during

Next Steps

research phases. Chemical synthesis is favoured for peptides of 15 or fewer amino acids in length, and quantities greater than 100kg. For longer sequences, chemical solid phase synthesis is used. Peptides longer than 50 amino acids, sometimes called mini-proteins, can be often produced by recombinant means. This provides an opportunity to develop new techniques for the synthesis of peptides between 30 and 50 amino acids for which chemical synthesis is too expensive and traditional recombinant methods are not appropriate.

Currently work is being done on a new fusion protein to patent the system. This new system aims at efficient purification and improvement of the productivity.

Contact

MarĂ­a Isabel Guerra Technology Transfer Manager

mguerrahevia@ing.uchile.cl +569 8472 3757 +562 2978 0739

www.cebib.cl

Hu m an he al th

A Treatment for Alcoholism

Research Group University University of Chile Researchers Juan A. Asenjo Barbara Andrews Contact techtransfer@cebib.cl mguerrahevia@ing.uchile.cl +562 29780739

Effective and long-term effect therapy against alcohol addiction

Potential Market Healthcare providers with addiction units. Pharmaceutical industry.

Therapy development.

Market Size According to the World Health Organization Report on Alcohol and Health (2014), 55% of the world’s population aged 15 or more consume alcohol, and 11.5% of these users have weekly episodes of consumption, which make them potential alcoholics. Alcohol consumption is related to more than 200 health conditions. Drinking alcohol is

associated with a risk of developing health problems such as mental and behavioural disorders, including alcohol dependence, major noncommunicable diseases such as liver cirrhosis, some cancers and cardiovascular diseases, as well as injuries resulting from violence, road clashes and accidents.

Pharmaceutical, and medical.

1

2

3

Development stage TRL 5 / Validated component in relevant environment.

Global population aged 15 or more Intellectual property No patents.

45%

55% Alcohol consumers

www.cebib.cl

Industry

Opportunity

Description The therapy against alcoholism consists of an intravenous injection of a solution containing viral vectors. These vectors will cause an effect specifically on the liver. Three different types of viral vectors have been developed: serotype 5 adenoviral vector, serotype 2 adeno-associated and serotype 8 adeno-associated. These viral vectors contain an antisense RNA or shRNA technology, whose genetic sequences inhibit long-term production of the alde-

Relevant Characteristics The therapy causes an adverse long-term physical reaction to alcohol, consisting of headaches, nausea, vomiting, tachycardia, hypotension and/or facial flushing. Therefore, patients have their tolerance to alcohol strongly reduced and decrease their consumption. Currently, the main treatment is the drug Disulfiram (inhibits the activity of ALDH2 and acts on cells throughout the body).

Its daily-based administration presents adherence problems, so its use is reduced. It also causes side effects such as hypertension and sensory and motor neuropathy.

hyde dehydrogenase (ALDH2) enzyme.

This enzyme participates in ethanol metabolism and its inhibition leads to a strong adverse reaction. In other words, patients have less alcohol tolerance and strongly reduce their consumption. The alcoholism therapy has been successfully tested in animal cells in vitro and in animal models. In addition, preclinical trials have been carried out using serotype 5 adenoviral vector with successful results.

Due to the increase of the alcoholic population in the world, an effective therapy is required to help lower consumption in alcoholics. This technological solution produces a very unpleasant physical reaction when the patient consumes alcohol since it acts specifically on the liver which is the organ responsible for the metabolism of alcohol. The main advantage over other drugs is that this therapy has limited side effects and the one-dose administration has a longterm effect (6 months), favoring therapy adherence.

Next Steps The effectiveness of the therapy has been proven successful at preclinical level studies in animal models. The next step is Phase I clinical trials in humans.

Contact

MarĂ­a Isabel Guerra Technology Transfer Manager

mguerrahevia@ing.uchile.cl +569 8472 3757 +562 2978 0739

www.cebib.cl

En zy m es

Antarctic Enzymes Commercial cryophilic enzymes from Antarctic krill and bacteria Research Group University University of Chile Researchers Juan A. Asenjo Barbara Andrews Ă lvaro Olivera Contact techtransfer@cebib.cl mguerrahevia@ing.uchile.cl +562 29780739

Potential Market Production of detergents and soaps. Biological polishing, decoloration by washing and antipilling in the textile industry. Food industry (dairy, juices, meat, beer, wine, cheese and butter). Biotechnology industry, for bioremediation in places that have seasonal variations

USD 8.1 billion

2015 www.cebib.cl

Industry Detergents, textile, chemical and others.

1

Market Size

2

3

Development stage

The world market for enzymes was valued at US$4.8 billion in 2014 and is expected to increase up to US$10 billion by 2020, growing at a CAGR of 8% from 2015 to 2020.

The proteases accounted for 27% of the global enzyme market in 2014, and the proteases for detergents segment are expected to grow at a CAGR of 11.5%.

In particular, Xylanase is used for the transformation of ligno-

Enzymes Global Market

in temperature. Chemical industry, for processes involving temperature-sensitive reagents and products. Pulp and paper processing.

Pharmaceutical industry, for cleaning external wounds. Cosmetics industry.

cellulosic biomass (biofuels, food, textile and paper pulp treatment), treatment of agricultural waste, and in the food industry. Commercial subtilisin is used in washing powders and the pet food industry for the treatment of whey. Trypsin is used for wound treatment, protein sequencing, preparation of bacterial media and leather processing.

USD 10.0 billion

2020

USD17.5 billion

2024

TRL 5 / validated component in relevant environment.

Intellectual property Patent application 61/150,545 (EPO) and 60/954,198 (USA), patent 10/896,010 (USA).

Description Set of polypeptides from genetically modified enzymes obtained from Antarctic microorganisms –bacteria and krill-, able to function at low temperatures. By using protein engineering, the activity and stability of the enzymes at low temperature was improved in comparison to commercial and native enzymes. Xylanase, subtilisin and trypsin have been sequenced and cloned into expression vectors to be synthesized from Escherichia coli.

Opportunity Industrial enzymes are less efficient at low temperatures: conditions between 5°C and 20°C are adverse for their use, the optimum range being between 40°C to 60°C. Processes with increased temperatures present high risk of contamination and loss of production, and also have a negative impact on the environment. For processes at low temperatures,

Relevant Characteristics

High enzymatic activity at low temperature

Technology package complete and ready for industrial scale production. These enzymes have been patented so their use is protected.

current commercial enzymes would have to be used in concentrations up to 10 times higher than the required at optimal conditions to be truly efficient. This presents a significant opportunity for active enzymes at low temperatures, optimally between 5°C and 20°C, requiring low concentrations and, therefore, being a more efficient alternative.

Next Steps The recombinant production and the enzymatic properties are being optimized with protein engineering at laboratory level. The goal is to find a business partner to scale up the production.

Contact

María Isabel Guerra Technology Transfer Manager

mguerrahevia@ing.uchile.cl +569 8472 3757 +562 2978 0739

www.cebib.cl

Bi

g

Compressed Genomic File System Research Group University University of Chile University of Santiago Researchers Gonzalo Navarro Mauricio MarĂ­n Contact techtransfer@cebib.cl mguerrahevia@ing.uchile.cl +562 29780739

Transcriptomic and genomic compression data (biomedicine, ecology, microbiology, microbiome, etc.) The end-user market can be broken down into different areas: universities, research centers, go-

vernment institutions, hospitals and clinics, pharmaceutical and biotechnology companies, agri-genomic companies, forensic agencies, and fishery and aquaculture companies, among others.

Market Size The genomics market is poised to reach almost USD $ 20 billion by 2020, growing at a CAGR of 9.9% during the forecast period of 2015 to 2020. The growth of the overall market can be attributed to an increase in the investments, grants,

Medical and Academic.

2

3

Development stage and funds by the government, and increasing research in the field of genomics. The market segments with major growth rate drug discovery and development, diagnostics, personalized medicine, agriculture and animal research.

TRL 4 / Validation of laboratory components.

Global Genomic Market (2013-2020) Intellectual property

20.0 10%

2015

www.cebib.cl

Industry

1

USD BILLION

Efficient storage and management of high throughput DNA sequencing data

Potential Market

2020

Patent draft.

Da t

a

Opportunity

Description The Compressed Genomic File System consists of a file management system that keeps these documents in a compressed format using an optimized algorithm. The three fundamental characteristics that differentiate this system with other genome compressors are: (1) this tool is not only a compressor, but a file system, which allows a transparent use; (2) given its compression algorithm, its efficiency increases when data correspond to similar samples, such as populations studied under the same condition, or the same organism or microorganism; and (3)

Relevant Characteristics Compressed Genomic File System is transparent to the user, with high compression efficiency and low file transfer time. The user does not need to decompress the files for reading and analysis, unlike current solutions. It can incorporate different search tools and data processing as needed, so that the final solution will be aligned with market requirements.

Genoma Mayor will use the first functional prototype.

the access to data is continuous, not being necessary to decompress for its use or application integration. This last feature is essential, as it allows the user to make use of all the historical data of a research center. This is possible since all data will be stored occupying a fraction of the original space, allowing the user to have access to more information.

In addition, the data transfer rate is much lower, since it is proportional to the size of the compressed file. This is one of the most valued features by the users.

The development of new sequencing technologies, such as next-generation sequencing, have reduced the costs of sequencing and increased the efficiency of the process. Many projects based on genomics are producing large amounts of data that need to be stored, distributed and analyzed, creating a major challenge for researchers in biology and computer sciences. Globally, genomics is compared with three largest generators of Big Data: YouTube, Twitter and Astronomy. Currently, there are on the order of 106 sequenced human genomes. As the technology gets better and cheaper, between 100 million and two billion human genomes will be stored by 2025.

Faster sequencing technology produces a much higher volume of data with a much higher redundancy, which requires much more efficient compression (in terms of size and processing speed) than the current simple and non-standard methods available today.

Next Steps To test the Compressed Genomic File System with real data and in large quantities (relevant environment) and develop the technology platform that integrates complementary services.

Contact

MarĂ­a Isabel Guerra Technology Transfer Manager

mguerrahevia@ing.uchile.cl +569 8472 3757 +562 2978 0739

www.cebib.cl

i Sk n ca re

Atacama Cream Active compound from the desert for skin protection Research Group University University of Antofagasta Researchers Cristina Dorador Esteban Severino Contact techtransfer@cebib.cl mguerrahevia@ing.uchile.cl +562 29780739

Atacama cream: bioactives compounds for skin care

Potential Market Cosmetics with antioxidant and UV protection properties. Organic cosmetics. Sale of active ingredients for cosmetic companies.

Market Size

Cosmetics.

1

The growth in global economies and self-care lifestyles have caused a rise in the demand for skin and sun care products around the world, in different climatic conditions. This trend has encouraged the growth of the cosmetics market. Consumer concerns about potential side effects

of chemical ingredients have shifted the preference towards natural and organic skin-care products, particularly in the United States and Europe.

The global cosmetic market was valued at USD $ 460 billion in 2014 and will reach USD $ 675 billion by 2020, growing at a rate of 6.4%.

2

3

Development stage TRL 6 / Technology demonstrated in relevant environment, user testing (pilot plant).

Sun Care Market Intellectual property

Self Tanning

Patent draft.

15% After Sun Protection

www.cebib.cl

Industry

20%

65%

Sun Care Production

Opportunity

Description Different sources were explored in the Atacama desert to find microorganisms: soil, salt lakes, sediments and water. The bacteria found in the desert can resist high UV radiation and low water concentrations. This is possible by synthesizing compounds capable of binding to water molecules to prevent its loss, and a pigment that protects from UV radiation. Using these compounds, a line of cosmetic skin care products was created: Atacama Cream, developed by the Atacama Bioactives entrepeneurship.

The active principles have both moisturizing and UV protection properties. The pilot plant built for this purpose is operational. The products developed so far are: day and night moisturizing lotion, sun protection lotion, cleansing lotion, body lotion and alcohol gel.

Relevant Characteristics The biocompounds have been obtained from a natural organic source, unlike synthetic compounds, which are produced through chemical synthesis based on the molecular structure of the compound of interest. Our mechanism is more sustainable than other extraction methods of antioxidant compounds (algae or plants), because -once isolatedthe bacteria that produce the compounds of interest can be cultured in large-scale reactors.

Rising demand for natural and organic skin care products creates new opportunities for manufacturers to innovate and develop new products in accordance with current consumer preferences. In the cosmetic market, skin care (especially facial and body care) has the highest share. Key factors that influence consumers’ choice are the concern about sun damage, in particular the higher incidence of skin cancer, and the preference for multifunctional products (sun protection, antioxidant, moisturizing, antiage). Atacama Cream fulfills all these expectations: it contains antioxidants and UV protection biocompounds, extracted from a natural source.

Next Steps To increase the production level, achieving purer compounds by optimizing the culture conditions.

Contact

MarĂ­a Isabel Guerra Technology Transfer Manager

mguerrahevia@ing.uchile.cl +569 8472 3757 +562 2978 0739

www.cebib.cl

Bu ta no lp ct du ro n io

Butanol Production From alginate using Saccharomyces cerevisiae Research Group University University of Chile Researchers Barbara Andrews Contact techtransfer@cebib.cl mguerrahevia@ing.uchile.cl +562 29780739

Macroalgae to biobutanol: a novel, cost-effective conversion technology

www.cebib.cl

Market Butanol is a four-link hydrocarbon chain that is produced from biomass as bio-butanol or from fossil fuel as petrobutanol. The growing environmental awareness coupled with increasingly stringent governmental regulations are expected to boost the overall demand for bio butanol over the next few years.

The growing demand for bio-based butanol can be attributed to the advantages that it offers as a fuel.

These advantages include energy content almost equivalent to gasoline, non-hydroscopic, compatible with existing engine systems and

9.9 Billion by 2020

storage infrastructure, low vapor pressure and utility as feedstock for diesel, jet fuel and bio-gasoline.

Owing to such benefits, bio-based butanol is widely used as a biofuel in transportation and other industries and as in paints, coatings, adhesives, sealants, printing inks, textiles and plastics. Moreover, bio-based butanol can be blended at 16% by volume while ethanol can only be blended at 10% by volume. As a result of the above, it is expected that the global market for n-butanol will reach USD $ 9.9 billion by 2020 at a CAGR of 5.1% in the forecast period.

5.1% CAGR

Industry Fuels, chemicals, pain, textile, plastic.

1

2

3

Development stage TRL 2 / Technological concept already formulated.

Intellectual property Patent draft

Description It involves the construction of a Saccharomyces cerevisiae strain capable of degrading alginate to use it as a carbon source for the synthesis of butanol from brown seaweed carbohydrates. This yeast shows a high tolerance to alcohol toxicity. The technology involves the design and construction of a recombinant S. cerevisiae strain that incorporates the alginate degradation pathway. In addition, it includes an alginate lyase secretion pathway (endolytic and exolytic), and an Enter-Dourodoff synthetic pathway for degradation, transportation and integration of alginate as a carbon source. For butanol production, a cluster of six synthesis genes is designed (14 kb in total), using pyruvate as a substrate. In order to improve the production of butanol and reduce the toxicity of the cluster, the latter will be expressed in the mitochondria (compartmentalization strategy). Both pathways, alginate degradation and butanol biosynthesis, will be stable due to the use of genomic integration using homologous recombination in vivo. Currently, enzyme candidates cloning is being developed for this cluster of genes.

Opportunity Increasing environmental concern about petroleum derived products has prompted manufacturers to develop alternate methods to manufacture bio-based chemicals from biomass rather than from petroleum feedstocks. Moreover, the volatile petroleum-derived raw material prices have further augmented the overall need to develop chemicals from the easily available and cheap bio-based feedstock.

Butanol was tradionally produced

by ABE fermentation, the anaerobic conversion of carbohydrates by strains of Clostridium into acetone, butanol and ethanol. However, cost issues, the relatively low-yield and sluggish fermentations, as well as problems caused by end product inhibition and phage infections,

meant that ABE butanol could not compete on a commercial scale with butanol produced synthetically.

Today bio-butanol can be produced in large quantities at competitive prices using bio-based raw materials such as sugarcane, corn and cellulosic sugars among others.

However, a sustainable process requires biomasses which do not compete with food crop biomasses.

The latter has generated widespread interest, opening the opportunity to work with a recombinant Saccharomyces cerevisiae strain that produces butanol from alginate. Macroalgae is an interesting feedstock since it is high in carbohydrates and attractive for fermentation processes given the low content of lignin and the abundant presence of alginate

Contact

MarĂ­a Isabel Guerra Technology Transfer Manager

mguerrahevia@ing.uchile.cl +569 8472 3757 +562 2978 0739

www.cebib.cl

An xi tio n da ts

Seaweed antioxidants

University University of Chile Researchers MarĂ­a Elena Lienqueo Alejandro Buschmann Carolina Shene Alyson Leyton Contact techtransfer@cebib.cl mguerrahevia@ing.uchile.cl +562 29780739

Scalable process that deliver a high yield and cost-effective natural and powerful antioxidant

Potential Market Use as an antioxidant additive in various industry segments: nutraceuticals, food preservatives, cosmetics, animal feed preservatives.

Other potential markets include

Market Size In terms of revenue, the antioxidant market was valued at USD $ 2,2 billion in 2014 and is estimated to reach USD $ 3,2 billion by 2020, expanding at a CAGR of 5.6% over the forecast period. In terms of volume, the antioxidants market was

Industry Food, cosmetics and animal food industry.

1 valued at 75.500 tons in 2014 and is estimated to reach 103.300 tons by 2020, expanding at a CAGR of 5.3% over the forecast period. The market for natural antioxidants corresponds to 30% of the total market.

2

3

Development stage TRL 2 / Technological concept already formulated.

Global Antioxidants Market (2014-2020)

3.2

Intellectual property No patents.

2.2

2014

www.cebib.cl

applications in the medical industry as a biocompound with anticancer, antimicrobial and antibacterial properties.

USD BILLION

Research Group

2020

Description Phlorotannins are polyphenolic compounds that are only found in brown algae and are known for their various bioactive properties, e.g. antioxidant, antimicrobial, anticancer, anti-diabetes, anti-HIV, etc. Thus they have a great potential to be applied as medicine or nutraceuticals. Unlike conventional methods of phlorotannin extraction, our solution is based on the use of active enzymes isolated from the same brown algae, which increases yield, decreases cost associated with organic solvents and preserves the quality of antioxidants. Additionally, the purification step avoids the use of toxic solvents, making our process environmentally sustainable.

Relevant Characteristics The results obtained from our method show that phoratannins have higher antioxidant activity than synthetic and other natural antioxidants, and it is 20% more stable than BHT at high temperature.

Next Steps To demonstrate the excellent results obtained at the level of proof of concept in a pilot plant.

Opportunity One of the major challenges of the food industry is to preserve food. Food which contains edible oils will spoil when exposed to oxygen from the air due to oxidation reactions. This causes a progressive deterioration of food resulting in organoleptic changes, mainly smell and taste, a decrease in the nutritional quality and the formation of potentially toxic compounds. Additionally, a main trend in the industry is the use of healthier ingredients, such as whole grain instead of refined flour or enrichment with omega-3, which causes a negative impact on product shelf life.

Synthetic antioxidants, like BHA, BHT or TBHQ are widely used because they are highly effective and cheap.

However, long-term exposure to high doses of synthetic antioxidants may have potentially toxic effects, and they are known carcinogens, so their usage has to be limited.

Consumers’ desire for fewer artificial ingredients resulted in the removal of synthetic additives from many food formulations. Natural antioxidants are the alternative; however, they are costly to produce and do not have good performance at high temperatures, like the synthetic ones.

Our method offers a solution that satisfies all needs.

Contact

MarĂ­a Isabel Guerra Technology Transfer Manager

mguerrahevia@ing.uchile.cl +569 8472 3757 +562 2978 0739

www.cebib.cl

Nu e ac tr ut ica ls

Nutraceutical Flour from Llaita as Substrate Research Group University University of Antofagasta Researchers Benito Gรณmez Contact techtransfer@cebib.cl mguerrahevia@ing.uchile.cl +562 29780739

A novel ingredient in nutrition, with antioxidant and antiinflammatory properties

Market Nutraceutical and functional food and beverage, animal food. Flourbased foods.

Industry Nutraceutical and food.

Market Size 1 Functional foods and beverages comprise a significant market share.

Nutraceuticals are nutritional or functional foods that have physiological benefits and reducing risks of several diseases. Nutraceutical dietary supplements range from isolated nutrients and herbal products, to processed foods and beverages, to meet specific dietary requirements.

These characteristics make nutraceuticals very attractive to food and beverage companies due to the relatively high margin of application and corresponding minimum regulatory requirements.

Factors such as increased health problems, growth in key demographics, and increasing consumer desire for a healthy life and avoiding synthetic drugs are the main factors contributing to the growth of this market.

The global market for nutraceuticals was valued at USD $ 182 billion in 2015, and will reach USD $ 278 billion by the year 2021, which presents a CAGR of 7.3% from 2015 to 2021. In particular, the functional food segment in terms of revenue has a 31% market share in 2014.

Global Neutraceutical Market (2013-2020)

278 USD BILLION

2015

2021

3

Development stage TRL 4 / Validation of laboratory components.

Intellectual property No patents.

182

www.cebib.cl

2

Opportunity

Description The development of new natural food products with nutraceutical potential based on llaita flour.

These products are highly nutritious, because the llaita flour is composed of essential amino acids, polyunsaturated fatty acids and does not produce or contain cyanotoxins.

Llaita is a natural biomass from high Andean wetlands, formed by colonies of filamentous Nostoc commune cyanobacterium, which is suitable for

human consumption and is a natural nutrient source used by ancient Andean people of South America.

Llaita has already been isolated and cultured in the laboratory, and flour has been produced from this biomass, which could be used for the development of marketable products as noodles, cookies, bars or other.

Currently a cereal bar prototype has been developed.

Relevant Characteristics Flour produced from llaita, endemic biomass of northern Chile, with relevant features such as its rich nutraceutical composition (essential amino acids and polyunsaturated fatty acids). Suitable for the manufacture of products such as noodles, cookies, bars, etc.

Nutraceuticals and functional foods are at a global peak, in relation to the urgent search for new food sources for humanity indicated by FAO. It is important to consider that the strategic government health programs include healthy foods in Chile, particularly products generated from endemic species.

Next Steps Find a business partner who is interested in prototype from llaita flour as a raw material.

Contact

MarĂ­a Isabel Guerra Technology Transfer Manager

mguerrahevia@ing.uchile.cl +569 8472 3757 +562 2978 0739

www.cebib.cl

Ta i

lin

Tailings Wall Optimization for Mining Research Group University University of Chile Researcher Carlos Conca Contact techtransfer@cebib.cl mguerrahevia@ing.uchile.cl +562 29780739

Need: Ensure tailings management In a scenario where the ore grades are declining, the production of a tone of metal will involve not only higher unit consumption of scarce resources such as water and energy, but also generate as much waste.

Chile currently produces 1,400 million tons per day of tailings as a result of fine copper production and tailings production could double by 2035. This situation is replicated in the world, every 30 years the volume of tailings grows 10 times; the surface, 5 times; and the height of the walls of the tailings, 2 times.

The large volumes of waste produced at mining operations are expensive to manage: it is equivalent to about 10% of the total operational cost. The environmental risks of tailings failure are enormous: a leakage of toxic compounds through its walls would result in soil and water contamination. One of the great challenges for the mining industry in construction and tailings management is to minimize the impact of infiltrations and ensure the stability of deposits.

Industry Mining.

1

2

3

Development stage TRL 4 / Validation of laboratory components.

Million tons tailling waste per day in Chile

2016

2035

Intellectual property Patent application CL 201303565.

1.4

million tons

www.cebib.cl

2.8

million tons

gs

Solution: Support model of buildings tailings wall

Economical tailings design with high safety standards

Technology to support the building of tailings walls using the same waste rocks from the mine to raise the dam. The wall design incorporated different parameters such as tailings fluid characteristics (viscosity, yield, stress), geometry (wall size, height, angle of the slope, width of the dam) and characteristics of the rock being used (shape and stone size), which are considered on a mathematical model to predict how much tailing could go into the wall without transferring it. The model determines the limit position of fluid

penetration, of what it depends and how long it takes to reach it. This made it possible to design an economical technology with high safety standards. In mining operations, waste disposal is one of the main economic issues. The optimized design of tailings walls allows the reuse of mining waste for their construction and helps reducing storage costs between 5% and 15%.

The proof of concept was already developed and a prototype has been obtained.

Contact

MarĂ­a Isabel Guerra Technology Transfer Manager

mguerrahevia@ing.uchile.cl +569 8472 3757 +562 2978 0739

www.cebib.cl

He y av oi ls

Bioadditive for Heavy Oils Research Group University University of La Frontera

Potential Market Fuel additives for shipping industries or ground transportation.

Also applicable to industries which

require boilers, generators or other equipment that uses heavy oils for operation. Oil industries as sellers.

Researchers Rodrigo Navia Contact techtransfer@cebib.cl mguerrahevia@ing.uchile.cl +562 29780739

Shipping industry, ground transportation industry, oil industries.

Market Size 1 The market was valued at USD $ 5.4 billion in 2014 and is expected to reach USD $ 11.0 billion

by 2023, expanding at a CAGR of 8.3% between 2015 and 2023.

Global bioadditive Market (2015-2023)

Bioadditive for a longer life with better engine performance

2

3

Development stage TRL 8 / Production proved, validated and qualified.

11.0 Intellectual property

5.4 USD BILLION

Patents presented.

2015

www.cebib.cl

Industry

2023

Description Fuel additives are chemicals that are added to various fuels such as gasoline, diesel, jet fuel, kerosene and many others, in order to improve performance.

Such additives are responsible for reducing the effects of corrosion caused by fuels and improve their combustion properties. The technology provided by this development is an additive for heavy oils, derived from biodiesel from the plant Brassica napus (RAPS) in combination with metal oxides and an organic surfactant.

This mixture will provide an improvement in the quality of combustion by catalysts that will contribute to the combustion process, a surfactant which will help decrease the droplet size to improve atomization (airfuel mixture), and finally the biodiesel will grant greater lubricity, which together will reduce harmful emissions to the environment. The bioadditive has proven effective in laboratory tests, reducing by 65% the emission of particulate matter compared to pure diesel.

Note that the product formulation may be requested with a special mixing protocol if required by the customer, enabling to meet the specific needs of individual companies.

The main advantages provided by bioadditive are: • Reduction of pollutant emissions and costs of

using fuel • Reduce engine maintenance • Increase engine cleanliness • Increase energy efficiency.

Technology Assessment: The value of the technology under assessment methodology of real options (recovery of a call option), was evaluated in USD $ 5.37 million.

Contact

María Isabel Guerra Technology Transfer Manager

mguerrahevia@ing.uchile.cl +569 8472 3757 +562 2978 0739

www.cebib.cl